SynthesisCOPD2019
Airflow Obstruction and Cardio-metabolic Comorbidities.
Synthesis in COPD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Burden of chronic obstructive pulmonary disease among Indian adults: systematic review and meta‑analysis.BMC pulmonary medicine · 2026Pooled it
- Association between hypertension and impaired lung function among adults: A systematic review and meta-analysis.PloS one · 2026Pooled it
- The association of spirometric small airways obstruction with respiratory symptoms, cardiometabolic diseases, and quality of life: results from the Burden of Obstructive Lung Disease (BOLD) study.Respiratory research · 2023Pooled it
- Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis.Bulletin of the World Health Organization · 2022Pooled it
- Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT.Health technology assessment (Winchester, England) · 2025Trial
- Asthma and extrapulmonary comorbidities in a middle-aged general population: results from the SCAPIS study.BMJ open respiratory research · 2025Article
- Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study.BMJ open respiratory research · 2025Article
- Is 'Cardiopulmonary' the New 'Cardiometabolic'? Making a Case for Systems Change in COPD.Pulmonary therapy · 2024Article
- Development of airflow limitation, dyspnoea, and both in the general population: the Nagahama study.Scientific reports · 2022Article
- Restricted spirometry and cardiometabolic comorbidities: results from the international population based BOLD study.Respiratory research · 2022Article
- Editorial: Chronic inflammation, oxidative stress and lipoprotein metabolism in cardio-pulmonary continuum.Frontiers in cardiovascular medicine · 2022Article
- New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study.International journal of environmental research and public health · 2020Article
- In Patients with Mild-to-Moderate COPD, Tobacco Smoking, and Not COPD, Is Associated with a Higher Risk of Cardiovascular Comorbidity.International journal of chronic obstructive pulmonary disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction and often co-exists with cardiovascular disease (CVD), hypertension and diabetes. This international study assessed the association between airflow obstruction and these comorbidities. 23,623 participants (47.5% males, 19.0% current smokers, age: 55.1 ± 10.8 years) in 33 centers in the Burden of Obstructive Lung Disease (BOLD) initiative were included. 10.4% of subjects had airflow obstruction. Self-reports of physician-diagnosed CVD (heart disease or stroke), hypertension and diabetes were regressed against airflow obstruction (post-bronchodilator FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.